The Ledger / Gilead Sciences
Gilead Sciences
◼ Origin
Gilead Sciences charges $1,000 per pill for sofosbuvir — a hepatitis C cure that costs $4.29 to manufacture in India and $74 to produce in Egypt. A bipartisan Senate Finance Committee investigation found that Gilead had set the US price not based on development cost, market forces, or patient affordability, but based on what the traffic would bear from a fragmented insurance system too broken to negotiate. The investigation found R&D cost approximately $1 billion; Sovaldi earned $11.3 billion in its first year alone. Hepatitis C infects approximately 2.4 million Americans, disproportionately people who inject drugs and incarcerated populations — communities with the least political power to fight back. Patients who cannot pay — because they are uninsured, because their insurer denied coverage, because their state Medicaid program imposed restrictions — do not get cured. They develop cirrhosis, liver cancer, and die of a disease that is medically and technically curable for $4.29. This is not a pricing anomaly. It is the documented, deliberate operation of a patent-protection regime that allows private companies to convert publicly-funded scientific breakthroughs into extraction machines. The system that makes Gilead possible kills people. That is a policy choice, renewed every year Congress fails to act.
◼ Self-Made Verdict — YES
Gilead Sciences turned AIDS and hepatitis C into profit centers. They priced a hepatitis C cure at $84,000, charged $21,000 a year for an HIV prevention drug whose patents the government owned, and deliberately withheld a safer HIV drug for over a decade to block generic competition. The Senate investigated. The government sued. Gilead kept the money.
◼ Documented marks
01
Priced Sovaldi at $1,000/pill ($84,000 per treatment course) for a hepatitis C cure; an 18-month Senate Finance Committee investigation drawing on 20,000 internal documents found Gilead explicitly chose to "maximize revenue" and instructed staff to "not fold to advocacy pressure." Medicare spent $8.2B on these drugs in 18 months. (Senate Finance Committee, 2015)
02
Charged $21,388/year for Truvada (PrEP), a taxpayer-funded HIV prevention drug whose patents are held by the CDC — costing ~$6/month to manufacture. Gilead refused to pay royalties, forcing the U.S. government to sue its own contractor for patent infringement to recover the public investment. (Washington Post 2019; HHS/DOJ lawsuit 2019)
03
Internal Gilead emails from 2003 show the company knew successor drug TAF was safer for kidneys and bones than TDF, but deliberately suspended TAF development and slow-walked FDA milestones so it would launch just as TDF patents expired — forcing millions of patients to take a drug Gilead knew was more harmful while blocking generic competition. (STAT News, 2024)
04
Priced remdesivir at $3,120 per COVID-19 patient — despite at least $70.5M in NIH/taxpayer investment in its development — while running profit margins above 90%. ICER calculated Gilead could profitably sell the same drug at $310/course. Gilead lobbying hit record highs in Q1 2020 as a bill that would have required affordable pricing for taxpayer-funded drugs was stripped from COVID relief legislation. (Common Dreams, June 2020; STAT News, Oct 2020)
05
Priced lenacapavir — a twice-yearly HIV prevention injection approved by the FDA on June 18, 2025 — at $28,218 per person per year in the US. Academic analysis at IDWeek 2025 found generic manufacture cost: $25/person/year at scale. The ratio is 1,000x. UNAIDS responded: "It is beyond comprehension how Gilead can justify a price of $28,218." (UNAIDS, June 2025; IDWeek 2025 presentation)
06
Settled a five-year patent lawsuit with the US government in January 2025, accruing approximately $200 million toward resolution — less than one percent of the $3 billion in annual Truvada revenue Gilead generated in 2018 alone. The government had originally sought $1 billion+ for Gilead using CDC-patented PrEP technology without paying royalties. Terms not fully publicly disclosed. (Gilead SEC filings, Q1 2024; FiercePharma, Jan 2025)
No inheritance, or primary accounts documented for this billionaire yet.
◼ List of charges
01
Price Gouging Causing Death
15 – life
Statute: Setting prices for life-saving goods or services at levels that foreseeably cause rationing, denial of access, and documented fatalities.
Basis: $1,000/pill ($84,000/course) for hepatitis C cure in US; same pill $4.29 in India; bipartisan Senate investigation found pricing driven by revenue not access; states rationed treatment until patients' livers failed; ~15,800 Americans died of HCV per year (2008 CDC) while cure was available at $300/course
02
Corruption of Democracy
25 – life
Statute: Knowing and sustained interference with democratic processes — including manufactured election-fraud claims after losing a free election, fake-electors schemes, pressure on state officials to alter vote counts, incitement of insurrection to obstruct certification, and mass dissemination of falsehoods about election integrity — as documented by court findings, congressional reports, sworn testimony of former officials, and verifiable public-record falsehoods.
Basis: Refused to honor CDC patents on taxpayer-funded PrEP research, forcing the U.S. government to sue its own contractor to recover public investment.
03
Tax Evasion via Offshore Concealment
5 – 15 years
Statute: Use of shell companies, nominee structures, or offshore accounts to conceal taxable income or assets from revenue authorities.
Basis: In 2013 (year of Sovaldi FDA approval), Gilead transferred Sovaldi IP to Irish subsidiary incorporated in Ireland but tax-resident in the Bahamas (Double Irish structure). By end of 2015: $28.5B in untaxed foreign profits, $9.7B in deferred US taxes, effective foreign tax rate ~1%. ATF reported the structure increased Gilead pre-tax profits fivefold 2013-2015. Loophole closed by Ireland in 2015 budget.
Total sentence
45–171 years
That is
0.6–2.2 life sentences
(using 78 years as one life)
These are moral charges, not legal ones. The actual legal system has not — and will not — bring them.
More ledger entries